TNF inhibitor

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions? The NOR-DRUM trials (A and B) are the first randomized trials to assess…

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest…

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axial spondyloarthritis (ax-Spa), whether they are diagnosed with…

Who wouldn't like to predict the future?  In Abstract 0380, Dr. Nikiphorou et al studied sick leave in relationship to axSpA. Patients from the DESIR cohort with work-related data and up to 5…

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a…

Patients with axial spondyloarthritis (axSpA) often have increased absence from work as well as reduced productivity at work, which can have profound impacts for not only the affected individual and…

In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical…

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and…

The COVID-19 pandemic has presented a global challenge. Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections. Over the past…

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that proactive therapeutic drug monitoring, a newer treatment strategy where a…